The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.

abstract：BACKGROUND:Current gene therapy vectors such as viral, non-viral, and bacterial vectors, which are used for cancer treatment, but there are certain safety concerns and stability issues of these conventional vectors. Exosomes are the vesicles of size 40-100 nm secreted from multivesicular bodies into the extracellular e...

journal_title：Current cancer drug targets

authors： Pofali P,Mondal A,Londhe V

更新日期：2020-01-01 00:00:00

abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

journal_title：Current cancer drug targets

authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

更新日期：2020-01-01 00:00:00

abstract：:NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 ...

journal_title：Current cancer drug targets

authors： Mansour SMA,Ali SA,Nofal S,Soror SH

更新日期：2020-01-01 00:00:00

abstract：:Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

journal_title：Current cancer drug targets

authors： Declèves X,Amiel A,Delattre JY,Scherrmann JM

更新日期：2006-08-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Wild-type Wilms' tumor gene WT1 is expressed at high levels not only in most of acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, but also in various types of solid tumors including lung cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for tumor specific immunot...

journal_title：Current cancer drug targets

authors： Oka Y,Tsuboi A,Elisseeva OA,Udaka K,Sugiyama H

更新日期：2002-03-01 00:00:00

abstract：:Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

journal_title：Current cancer drug targets

authors： Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

更新日期：2013-07-01 00:00:00

abstract：:It has been estimated that greater than 35% of all human genes undergo alternative splicing. The process of alternative splicing is highly regulated and disruption of a splicing pattern can produce splice variants that have different functions. Certain splice variants that are associated with induction of cell death, ...

journal_title：Current cancer drug targets

authors： Mercatante DR,Sazani P,Kole R

更新日期：2001-11-01 00:00:00

abstract：:Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

journal_title：Current cancer drug targets

authors： Grunt TW,Mariani GL

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:Intestinal β-glucuronidase enzyme has a significant importance in colorectal carcinogenesis. Specific inhibition of the enzyme helps prevent immune reactivation of the glucuronide- carcinogens, thus protecting the intestine from ROS (Reactive Oxidative Species) mediatedcarcinogenesis. OBJECTIVES:Advancement...

journal_title：Current cancer drug targets

authors： Yousuf M

更新日期：2019-01-01 00:00:00

abstract：:The resistance of tumors to a number of structurally and functionally unrelated chemotherapeutic drugs has been a major obstacle for successful cancer chemotherapy. An important mechanism leading to multidrug resistance (MDR) is the overexpression of the 170 kDa P-glycoprotein (P-gp), which is a member of the ATP-bind...

journal_title：Current cancer drug targets

authors： Santos SA,Paulo A

更新日期：2013-10-01 00:00:00

abstract：:The epidermal growth factor (EGFR) and its receptor were discovered nearly 40 years ago. Over the past decade interruption of this pathway has been exploited in the treatment of various solid tumors. Antibodies that interfere with ligand binding to and dimerization of the EGFR (and small molecules that inhibit the EGF...

journal_title：Current cancer drug targets

authors： Astsaturov I,Cohen RB,Harari P

更新日期：2007-11-01 00:00:00

abstract：:Despite remarkable progress that has been made in the recent years in the treatment of gastrointestinal tumors, in particular colorectal cancer, the prognosis of pancreatic cancer remains dismal. Five years after diagnosis almost all patients have died. At early stages of the disease surgery is the only modality to ac...

journal_title：Current cancer drug targets

authors： Porzner M,Seufferlein T

更新日期：2011-07-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

journal_title：Current cancer drug targets

authors： Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

更新日期：2010-02-01 00:00:00

abstract：:One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...

journal_title：Current cancer drug targets

authors： González G,Lage A

更新日期：2007-05-01 00:00:00

abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

journal_title：Current cancer drug targets

authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

更新日期：2010-11-01 00:00:00

abstract：:Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal transduction from various growth factors and upstream proteins to the level of mRNA translation and ribosome biogenesis, with pivotal regulatory effects on cell cycle progression, cellular proliferation and growth, autophagy and angiogenes...

journal_title：Current cancer drug targets

authors： Ciuffreda L,Di Sanza C,Incani UC,Milella M

更新日期：2010-08-01 00:00:00

abstract：:Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

journal_title：Current cancer drug targets

authors： Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

更新日期：2003-12-01 00:00:00

abstract：:Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

journal_title：Current cancer drug targets

authors： Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

journal_title：Current cancer drug targets

authors： Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

更新日期：2018-01-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth,...

journal_title：Current cancer drug targets

authors： Stefanachi A,Leonetti F,Nicolotti O,Catto M,Pisani L,Cellamare S,Altomare C,Carotti A

更新日期：2012-06-01 00:00:00

abstract：:Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

journal_title：Current cancer drug targets

authors： Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

更新日期：2013-09-01 00:00:00

abstract：:MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles i...

journal_title：Current cancer drug targets

authors： Zheng N,Yang P,Wang Z,Zhou Q

更新日期：2017-01-01 00:00:00

abstract：:Actin was first identified in non-muscle cells only about three decades ago, and at about the same time, it was found that actin filaments were disrupted in the malignant transformed cells. The actin network is a rather complex, yet important structural and functional system of all eukaryotic cells. Actin filaments pr...

journal_title：Current cancer drug targets

authors： Rao J,Li N

更新日期：2004-06-01 00:00:00

abstract：:Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

journal_title：Current cancer drug targets

authors： Culig Z,Bartsch G,Hobisch A

更新日期：2004-08-01 00:00:00

abstract：BACKGROUND:Cathepsin D (CATD), one of the aspartyl endoproteinase involved in different physiological processes and signaling pathways, is accountable for metabolic breakdown of intracellular proteins, the activation of growth factors, hormones, and precursors of enzyme, the processing of antigens, enzyme inhibitors an...

journal_title：Current cancer drug targets

authors： Dubey V,Luqman S

更新日期：2017-01-01 00:00:00

abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

journal_title：Current cancer drug targets

authors： Vigushin DM,Coombes RC

更新日期：2004-03-01 00:00:00

abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...

journal_title：Current cancer drug targets

authors： Hermes N,Kewitz S,Staege MS

更新日期：2016-01-01 00:00:00

abstract：:In this early phase of the new era of molecularly targeted patient friendly cancer chemotherapy, there is a need for novel viable anticancer molecular targets. The MDM2 oncoprotein has been validated as a potential target for cancer drug development. MDM2 amplification and/or overexpression occur in a wide variety of ...

journal_title：Current cancer drug targets

authors： Buolamwini JK,Addo J,Kamath S,Patil S,Mason D,Ores M

更新日期：2005-02-01 00:00:00